How effective is testosterone replacement therapy in premenopausal women with severe androgen deficiency?

2006 ◽  
Vol 2 (8) ◽  
pp. 432-433 ◽  
Author(s):  
Henry Burger
Keyword(s):  
Replacement Therapy ◽  
Premenopausal Women ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency

Correction of Androgen Deficiency in Men with Type 2 Diabetes

2021 ◽  
Vol 16 ◽  
Author(s):  
Volodymyr Pankiv ◽  
Tetyana Yuzvenko ◽  
Nazarii Kobyliak ◽  
Ivan Pankiv
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Control Group ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Testosterone Undecanoate ◽  
Testosterone Levels

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities. Aim: to investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency. Materials and methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months. Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l). Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

scholarly journals Influence of Testosterone Replacement Therapy on Metabolic Disorders in Male Patient with Type 2 Diabetes Mellitus and Androgen Deficiency

2014 ◽  
Vol 2 (4) ◽  
pp. 601-607
Author(s):  
Shota Janjgava ◽  
Tamar Zerekidze ◽  
Lasha Uchava ◽  
Elene Giorgadze ◽  
Ketevan Asatiani
Keyword(s):  
Blood Pressure ◽  
Lipid Profile ◽  
Replacement Therapy ◽  
Free Testosterone ◽  
Testosterone Replacement ◽  
Controlled Study ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Antidiabetic Therapy ◽  
Group I

INTRODUCTION: Multiple epidemiological studies have shown that low testosterone levels are associated with and predict the future development of T2DM.AIM: The aim of study was to show the influence of testosterone replacement therapy on anthropometric characteristics, glycosylated hemoglobinlevel level, blood pressure and dyslipidemia in patients with T2DM and Androgen deficiency.MATERIALS AND METHODS:  From 125 male patients with T2DM were randomized 85 subjects with age 49.8 ± 6.74 and BMI from 35.83 ± 3.65 kg/m2 in placebo-controlled study. We divided patients into two groups: 1) Treatment group, where was used testosterone replacement therapy. 2) Placebo group, where was used placebo. In both groups was added Life style modification, but Antidiabetic therapy was unchanged.RESULTS: After six months of treatment we repeated the diagnostic assessments: lipid profile was improved in both groups but in group I it was statistically significant. Free testosterone level increased in all groups but in group I it was statistically significant. HbA1c decreased in both group but in group I we had the best result. Blood pressure was reduced in both groups, results were similar.CONCLUSION: Our study demonstrated that it is possible to regulate blood pressure, lipid profile, HbA1c, BMI - by raising testosterone in diabetic men with androgen deficiency.

scholarly journals Why Is Androgen Replacement in Males Controversial?

2011 ◽  
Vol 96 (1) ◽  
pp. 38-52 ◽  
Author(s):  
Glenn R. Cunningham ◽  
Shivani M. Toma
Keyword(s):  
Clinical Trials ◽  
Replacement Therapy ◽  
Evidence Synthesis ◽  
Epidemiological Studies ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Testosterone Levels ◽  
Potential Risks ◽  
Low Testosterone

Context: Symptoms and signs consistent with androgen deficiency and low testosterone levels are recognized frequently in clinical practice. Recent population-based epidemiological studies indicate that low testosterone levels in men are associated with increased morbidity and mortality. The clinician must be able to counsel patients to help them determine whether testosterone replacement therapy is appropriate for them. Evidence Acquisition: The authors have conducted a literature search in PubMed, and we have reviewed references in the multiple systematic reviews and meta-analyses that have been published on this topic. Evidence Synthesis: We have attempted to provide the reader with an appreciation of the evidence that can be used to support the diagnosis of androgen deficiency, the efficacy of treatment, the potential risks of treatment, the therapeutic options, and the recommendations for monitoring treatment. Conclusions: We think that published clinical experience justifies testosterone replacement therapy in males who have not initiated puberty by age 14 and in males with low testosterone levels due to classical diseases of the hypothalamic-pituitary-gonadal axis. The benefit:risk ratio is less certain in older men and in those with chronic diseases associated with low testosterone levels. The decision to treat in this setting is much more controversial because there are few large clinical trials that have demonstrated efficacy and no large clinical trials that have determined potential risks of increasing the incidence of clinical prostate cancers or cardiovascular events. We provide a critical review of the evidence that supports treatment and potential risks and ways to reduce the risks if the physician and patient elect testosterone replacement.

Sign in / Sign up

Export Citation Format

Share Document